

1 Title: Pooled Saliva Specimens for SARS-CoV-2 Testing

2

3 Running Title: Pooled Saliva for COVID-19 Screen

4

5 Bidisha Barat¹, Sanchita Das¹, Valeria De Giorgi², David K. Henderson³, Stacy Kopka⁴, Anna F. Lau¹, Tracey

6 Miller⁴, Theresa Moriarty⁵, Tara N. Palmore³, Shari Sawney⁵, Chris Spalding³, Patricia Tanjutco⁵, Glenn

7 Wortmann⁵, Adrian M. Zelazny¹, and Karen M. Frank¹

8

9 ¹Department of Laboratory Medicine, ²Department of Transfusion Medicine, and ³Hospital Epidemiology
10 Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA

11 ⁴Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research,
12 Rockville, MD, USA

13 ⁵MedStar Washington Hospital Center, Washington, DC, USA

14

15 Corresponding Author

16 Karen M Frank, MD, PhD

17 Dept of Laboratory Medicine

18 Clinical Center, NIH

19 Room 2C306, Bldg 10

20 10 Center Drive

21 Bethesda, MD 20892

22 karen.frank@nih.gov

23

24 **Abstract:**

25 We evaluated saliva (SAL) specimens for SARS-CoV-2 RT-PCR testing by comparison of 459 prospectively
26 paired nasopharyngeal (NP) or mid-turbinate (MT) swabs from 449 individuals with the aim of using
27 saliva for asymptomatic screening. Samples were collected in a drive-through car line for symptomatic
28 individuals (N=380) and in the emergency department (ED) (N=69). The percent positive and negative
29 agreement of saliva compared to nasopharyngeal swab were 81.1% (95% CI: 65.8% – 90.5%) and 99.8%
30 (95% CI: 98.7% – 100%), respectively. The sensitivity increased to 90.0% (95% CI: 74.4% – 96.5%) when
31 considering only samples with moderate to high viral load (Cycle threshold (Ct) for the NP \leq 34). Pools
32 of five saliva specimens were also evaluated on three platforms: bioMérieux NucliSENS easyMAG with
33 ABI 7500Fast (CDC assay), Hologic Panther Fusion, and Roche COBAS 6800. The median loss of signal
34 upon pooling was 2-4 Ct values across the platforms. The sensitivity of detecting a positive specimen in
35 a pool compared with testing individually was 100%, 93%, and 95% for CDC 2019-nCoV Real-Time RT-
36 PCR, Panther Fusion® SARS-CoV-2 assay, and cobas® SARS-CoV-2 test respectively, with decreased
37 sample detection trending with lower viral load. We conclude that although pooled saliva testing, as
38 collected in this study, is not quite as sensitive as NP/MT testing, saliva testing is adequate to detect
39 individuals with higher viral loads in an asymptomatic screening program, does not require swabs or
40 viral transport media for collection, and may help to improve voluntary screening compliance for those
41 individuals averse to various forms of nasal collections.

42

43 **Introduction:**

44 A coronavirus outbreak (COVID-19) that was first reported in late December 2019 rapidly spread
45 worldwide resulting in a pandemic. There are > 29 million SARS-CoV-2 infections and > 900,000 related
46 deaths worldwide, with >6 million infections and >194,000 deaths in the United States (1). Screening,

47 testing, and contact tracing are essential for patient management and to reduce further spread of
48 disease. Diagnostic testing for SARS-CoV-2 has been challenging throughout the course of the pandemic
49 for numerous reasons such as supply shortages. For symptomatic patients, a highly sensitive, specific,
50 and reliably accurate assay is important, and the choice of specimen type can impact assay performance
51 (2). The Centers for Disease Control and Prevention (CDC) currently lists the following upper respiratory
52 specimen types as acceptable: nasopharyngeal swab, anterior nares, mid-turbinate, oropharyngeal (OP),
53 and NP/nasal wash/aspirates, with the NP swab often considered the preferred method for diagnostic
54 testing and the collection method to which other specimen types have been compared (3-5). However,
55 there is inconvenience associated with NP and OP swab collection including patient discomfort (3, 6),
56 some risk of exposure to healthcare personnel, the requirement for swabs, and the need for personal
57 protective equipment (PPE). Alternative specimen sources, such as anterior nares, have been listed as an
58 acceptable specimen type since early in the pandemic even though reported sensitivity is only about
59 86% (2). Saliva, however, which can be easily self-collected by patients and is non-invasive has not been
60 studied adequately. The goals for SARS-CoV-2 testing in asymptomatic vs symptomatic individuals
61 differ, with high participation rate and ease of collection being important considerations for screening
62 an asymptomatic population. This is particularly relevant as there is an urgent desire to open schools
63 and businesses and to promote economic recovery. At our institution, we have had frequent requests to
64 offer saliva testing for employees who did not voluntarily agree to NP or MT collection because of a
65 medical condition or personal aversion. We hope to engage these individuals in our voluntary screening
66 program by providing a suitable alternative specimen type. When this study began, saliva was not an
67 accepted specimen type, an Emergency Use Authorization was required by the Food and Drug
68 Administration for testing saliva, and procurement of saliva collection devices with stabilizers was
69 limiting. Previously published studies on saliva testing for COVID-19 vary from 71 to 100% in their
70 reported percent positive agreement or sensitivity of saliva compared with NP (Table S1) (2-4, 6-19).

71 Importantly, the tested population, the saliva collection method, and the processing protocol have
72 varied between the studies, making comparison of results challenging. The number of individuals tested
73 in some studies was relatively low; therefore, performance of saliva warrants additional study to
74 determine the robustness of saliva testing. Here, in a low-prevalence geographical region, we collected
75 samples from a drive-through collection center for symptomatic or exposed employees and during ED
76 visits to evaluate saliva for detection of SARS-CoV-2 infection, with a goal to add saliva as an option at
77 our institution for asymptomatic employee screening. We also demonstrated that pooled saliva testing
78 provides acceptable sensitivity on three separate platforms, two of which are high-throughput
79 instruments.

80

81 **Methods:**

82 **Study Subjects:** Subjects were enrolled at two sites. At the NIH, adult employees presenting to a drive-
83 through testing center due to symptoms or exposure were invited to provide SAL at the time of the NP
84 collection. Criteria for referral to the car line included symptoms consistent with potential COVID-19
85 after review by occupational medicine service or recent high-risk exposure to an individual known to be
86 infected with SARS-CoV-2. After giving informed consent, participants were instructed to provide 3-5 mL
87 of saliva using the drooling method into a sterile tube without any stabilizer or solution. Participants
88 were asked to avoid coughing or clearing the throat, if possible, during the collection. Saliva was
89 collected without restriction on timing or intake of food. Following the saliva collection, the NP swab
90 was collected by a healthcare provider. Six participants who were known to be positive returned on
91 subsequent dates and provided paired MT and SAL samples, avoiding the need for the potentially
92 uncomfortable NP collection with an aim to improve study participation, for a total of seven MT
93 specimens. At the Washington Hospital Center, subjects who presented to the emergency department

94 with symptoms consistent with COVID-19 were invited to participate. The study was approved by the
95 institutional review boards for both participating institutions.

96

97 **Specimen Collection and Processing:**

98 Saliva samples collected in sterile containers without additives were stored at 4°C until testing, and were
99 tested within 36 hours of collection with residual volume from the samples being frozen at -70°C. NP
100 samples were collected with flocked swabs (Puritan) into 3 mL of viral transport media (Corning) and
101 were tested within 12 hours of collection. Saliva/NP/MT specimens (200 µL) were extracted using the
102 NucliSENS easyMAG platform (bioMérieux, Marcy l'Etoile, France) resulting in 50 µL of eluate. All saliva
103 samples were tested only at the NIH laboratory. If a saliva sample was thick and hard to pipet, it was
104 treated with Mucolyse (ProLab Diagnostics, Richmond Hill, ON, Canada) 1:1 with heating at 35°C for 15
105 minutes. Following digestion, 400 µL was extracted by easyMAG for a 50 µL eluate. After testing of the
106 specimens collected in the ED, the remaining NP samples were sent to the NIH laboratory for retesting
107 on easyMAG/ABI 7500 platform, if specimen was available.

108

109 **SARS-CoV-2 Assay:**

110 Nucleic acid from individual specimens was extracted from 200 µL of Saliva/NP/MT specimens using the
111 NucliSENS® easyMAG® platform (bioMérieux, Marcy l'Etoile, France) with an elution volume of 50 µL.
112 PCR was performed on the Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher
113 Scientific, Waltham, MA) (20). The assay utilized primer/probe sets for nucleocapsid protein, 2019-
114 nCoV_N1 and 2019-nCoV_N2, and the human RNase P (RP) as an internal control to ensure that
115 extraction and amplification was adequate as described. Cycle threshold (Ct) values were recorded for
116 N1, N2 and RNase P for each sample. Samples were considered positive for SARS-CoV-2 when both N1
117 and N2 targets were detected with Ct count <40. The positive signal for N1 or N2 alone was defined as

118 an indeterminate result. The Panther Fusion® SARS-CoV-2 Assay is a real-time RT-PCR assay with
119 detection of two conserved regions of the ORB1ab gene in the same fluorescence channel and was
120 performed on the Panther Fusion (Hologic, Inc., San Diego, CA). The cobas® SARS-CoV-2 real-time RT-
121 PCR test was performed on the cobas 6800 instrument (Roche Molecular Diagnostics, Pleasanton, CA).
122 Amplification of SARS-CoV-2 target nucleic acid is achieved by the use of a two-target RT-PCR, one from
123 the SARS-CoV-2 specific ORF1 a/b non-structural region (target 1) and one from a conserved region of
124 the envelope E-gene common to all SARS-like coronaviruses (pan-Sarbecoviruses) (target 2). The pan-
125 Sarbecovirus detection sets will also detect the SARS-CoV-2 virus. Specimens collected in the ED were
126 tested on one of the platforms at the MedStar Washington Hospital Center Laboratory: BioGX SARS-
127 CoV-2 Reagents for BD MAX™ System (Franklin Lakes, NJ, USA), Xpert® Xpress SARS-CoV-2, Cepheid's
128 GeneXpert® Systems (Sunnyvale, CA, USA), DiaSorin Molecular Simplexa™ COVID-19 Direct real-time RT-
129 PCR, LIAISON® MDX instrument (Stillwater, MN, USA) or sent to a reference laboratory that uses the
130 QuantStudio (Thermo Fisher, Waltham, MA).

131

132 **Pooling Saliva:**

133 Equal volumes of saliva from five subjects were pooled into a single tube. Proteinase K, 20 mg/mL
134 (Invitrogen by Thermo Fisher Scientific, Waltham, MA) was added at a ratio of 12.5 µL per 100 µL
135 volume, followed by vortexing, heating for 5 minutes at 95°C, and brief centrifugation. The following
136 volumes of supernatant were loaded onto three different platforms: 400 µL onto NucliSENS easyMAG
137 (bioMérieux, Marcy l'Etoile, France), 500 µL onto the Panther Fusion (Hologic, Inc., San Diego, CA), and
138 600 µL onto the COBAS 6800 (Roche, Pleasanton, CA). Individual samples that were thick were excluded
139 from pooling and run as individual samples only, so none of the samples in the pool were treated with
140 mucolyse prior to pooling.

141

142 **Statistical Methods:**

143 Wilcoxon signed-rank test was used to compare the cycle threshold (Ct) values. The 95% confidence
144 intervals were calculated using the hybrid Wilson/Brown method. The correlation of Ct values between
145 NP/MT and saliva was assessed using Pearson correlation coefficient and represented graphically with
146 linear regression. A two-tailed T test with $p < 0.05$ was considered statistically significant. The negative
147 RT-PCR of the target gene was set at the Ct value of 40 for the statistical analysis. The NP swab test
148 result was used as the reference method for the assessment of test agreement. For analysis of age
149 range, 448 subjects of 449 were included because one subject's age was not available. All statistical
150 analyses were performed using GraphPad Prism version 8 (GraphPad Software, San Diego, CA). Only Ct
151 values derived from testing on a single platform at NIH were included in the statistical analysis, with the
152 only exception being the one calculation of percent positive agreement for the subset of higher viral
153 load specimens ($Ct \leq 34$) for which the results from all platforms were considered, if the NP specimen
154 was not also tested at NIH.

155

156 **Results:**

157 This study includes a total of 918 specimens (459 pairs) collected from 449 individuals between July, 13,
158 2020 and September 18, 2020. Of the total, 390 paired sets were collected from the NIH drive-through
159 testing center and 69 were collected from the MedStar Washington Hospital Center ED. Participants in
160 the drive-through testing center were symptomatic or had a recent high-risk COVID-19 exposure, and all
161 patients in the ED had symptoms suggestive of possible COVID-19. The median age of participants was
162 42 (range 21 – 88 years), with 59% female, 41% male (Table S2). Of the 459 saliva samples, 75 were
163 thick (57/390 (15%) from the drive-through and 18/69 (26%) from the ED) and were treated initially with
164 mucolyse prior to individual testing. A total of 18 failed the initial extraction (13/390 (3%) from drive-
165 through and 2/69 (3%) from the ED) and testing was repeated (Tables S3, S4). The percent positive and

166 negative agreement of saliva compared to reference collection of NP/MT swab (440 NP and 7 MT) were
167 81.1% (95% CI: 65.8 % - 90.5%) and 99.8% (95% CI: 98.7% - 100%) respectively (Table 1). When
168 considering samples with moderate to high viral load only, excluding the lower viral load specimens
169 (defined as Ct of NP/MT \leq 34), the percent positive agreement increased to 90.0% (95% CI: 74.4% –
170 96.5%). See Table S5.

171
172 A comparison of the Ct of N1 for NP/MT and SAL for all samples tested on the NIH platform showed a
173 higher viral load in the NP/MT samples compared to the SAL samples with median Ct of 26 for NP/MT
174 compared to 31 for saliva (Figure 1A, 1B). Similar results were obtained upon comparison of N2 results
175 for NP and SAL (Figure S1). There was a moderately good correlation of NP/MT Ct values with matched
176 saliva (Figure S2). There was very good correlation for the N1 and N2 Ct values for both NP/MT and SAL
177 (Figure S3A, S3B). Our analysis of the Ct values for the control RP gene indicates that the samples of
178 different specimen types were adequate and the difference in Ct values of saliva vs NP/MT are not due
179 to differences in human material obtained during the collection as saliva had slightly lower median Ct,
180 meaning slightly stronger RP signal even though the SARS-CoV-2 signal is slightly less for saliva (Figure
181 1C).

182
183 To evaluate the pooling approach to testing, equal volumes of saliva were combined into a single tube,
184 excluding samples too thick to pipet well, followed by treatment with proteinase K (21, 22). Three
185 different platforms were tested to increase our options for automated workflow for screening, the CDC
186 assay on the bioMérieux NucliSENS easyMAG/ABI 7500Fast platform, the Hologic Panther Fusion, and
187 Roche COBAS 6800. For pooled testing on any platform, the results of the pool were compared to the
188 individual saliva samples tested on the easyMAG/ABI 7500 platform, as that was our gold standard in
189 the lab for individual saliva testing. For a pooled sample, the average loss of signal was 2-4 Ct values

190 when compared with the individual sample for each platform (Figure 2A-C, Table S6). The sensitivity of
191 detecting a positive specimen in a pool compared with testing individually was 100%, 93%, and 95% for
192 easyMAG/ABI 7500, Hologic Panther Fusion, and Roche COBAS 6800 respectively, with decreased
193 detection of samples with lower viral load as expected. The correlation of Ct values for individual
194 samples versus pooled samples was slightly better for the CDC assay than for the Panther or COBAS
195 assays (Figure S4 A-C). It is possible that future optimization of the processing steps for the automated
196 platforms may lead to improved sensitivity.

197

198 **Discussion:**

199 With the unprecedented number of deaths worldwide due to a coronavirus infection, screening, testing,
200 and contact tracing for SARS-CoV-2 are essential. Developing new diagnostic measures for detection of
201 COVID-19 is of critical importance to meet the global public health needs of COVID-19 testing. Because
202 saliva can be self-collected, specimen collection can be simplified whereby the number of health care
203 professionals in PPE in special collection centers can be reduced (4, 6, 23). Beginning May 2020, the
204 NIH instituted a program to test asymptomatic employees weekly, but voluntary participation rate was
205 far lower than desired. Some individuals found the NP or MT collection too uncomfortable for routine
206 testing on a weekly basis. The goal of this study was to evaluate and add saliva as an alternative testing
207 option for NIH employee asymptomatic screening only; not to replace our existing test algorithm for
208 symptomatic patients. However, given the low rate of infections identified through our asymptomatic
209 testing program (0.1% positivity rate), we enrolled symptomatic and high-risk exposed individuals
210 through our drive-through collection site (5% positivity rate) and from a local ED (23% positivity in our
211 study set). During the course of the COVID-19 pandemic, individual laboratories have been required to
212 validate many different platforms due to supply shortages, multiple collection devices, and various
213 specimen types. Although there are a number of published studies comparing specimen types, each

214 study has a limited number of subjects and there are variations in collection methods, participant
215 characteristics, and testing platforms. In order to be approved to conduct saliva testing, based on
216 regulatory guidelines at the time, we were required to compare paired NP and saliva collections from
217 the same individuals, not only to validate saliva as an acceptable specimen type on our instrument.
218
219 The range of reported sensitivity or percent positive agreement of the saliva collection method, most
220 often compared to NP swab, varies widely from 71 to 100% and is too broad to make a specific guideline
221 without further refinement of the analysis (2-4, 6-19). While our study and others show the
222 acceptability of testing saliva, important variables need to be considered when reviewing various
223 reported conclusions. These include severity of disease (asymptomatic to severe disease in hospitalized
224 patients), method of collection (collection upon waking before any food or water intake, versus forced
225 cough collected later in the day, versus drooling technique with no restriction on food/water intake at a
226 random time later in the day), the gold standard or reference method for comparison in each study (NP
227 versus NP/OP, versus MT), healthcare provider collected versus self-collected NP, addition of stabilizing
228 agent, processing steps, RNA extraction process, and testing platform. Each of the studies alone is
229 limited by which group of individuals was tested, the time and method of collection, and processing
230 methods (4, 19). Some studies were limited by the inability of individuals to elicit a cough when
231 requested (14), and there is a need to consider potential preanalytical errors caused by home-collected
232 samples. It is possible that viral RNA extraction as well as RT-PCR efficiency might differ with the use of
233 different preservation solutions based on their ability to protect viral RNA from degradation as well as
234 their extraction chemistry (24).
235
236 Some studies have shown a lower viral load in saliva (13, 16, 17), but other studies showed similar viral
237 loads between specimens or better viral loads in saliva (6). Studies have reported that higher viral loads

238 were seen in patients with more severe disease (6, 7). In our study, the Ct values were on average
239 higher in saliva (indicating a lower viral load) compared with NP. Comparison of first morning saliva
240 versus a randomly timed collection was not an option for our study, given the consenting workflow.
241 Saliva samples may be less optimal when not a first morning collection, for asymptomatic individuals, for
242 those without food/water restriction, and for those later in the course of disease. Importantly, the range
243 of viral load in the specimens in a small study can greatly affect the final calculated percent positive
244 agreement because the specimens with higher viral loads are more likely to be detected by both NP/MT
245 and SAL; therefore, studies with a higher median viral load across most specimens will show higher
246 percent positive agreement than a study with a lower median viral load. The percent positive agreement
247 on our study changed from 81% to 90% when only moderate to high viral load samples were included in
248 the analysis. A meta-analysis that accounts for collection methods, patient population, and processing
249 methods will lead to a more comprehensive understanding of the usefulness of SARS-CoV-2 saliva
250 testing.

251
252 In order to provide high volume screening using saliva, there was a decision at our institution made to
253 pool the samples. We had previously demonstrated that pooling of ten NP samples resulted in only a
254 slight drop in sensitivity (losing an average of 3 Ct values) (25). For saliva, we chose to pool only five
255 saliva samples because the saliva specimen as collected already resulted in a lower sensitivity. When
256 pooling was applied, sensitivity was 100%, 93%, and 95% for the easyMAG/ABI 7500, Panther Fusion,
257 and COBAS 6800, respectively. To date, only a few studies have evaluated the pooling of saliva (26, 27).
258 Pooling conserves reagents and allows for higher throughput. The difference in Ct values between
259 individual saliva samples and pooled saliva samples was 2-4 in our study. When combined with the
260 lower rate of detection of infected individuals using saliva in our study, one might conclude that the use

261 of pooled saliva on an automated platform, albeit with a slightly lower sensitivity, might be acceptable
262 to promote compliance for screening.

263
264 The limitations for our study included the low number of positive participants, testing of symptomatic
265 patients to determine an approach for screening the asymptomatic population, and the combined use of
266 two collection sites (drive-through center and ED). The positive specimens include seven MT of the total
267 38 positives, to increase likelihood of participation in the study. All positive NP samples from the ED did
268 not have a Ct value from the easyMAG/ABI 7500 platform, as not all samples were available for repeat
269 testing. For this reason, only data from the easyMAG/ABI 7500 platform are included in the figures that
270 compare Ct ranges.

271
272 A challenge for all centers offering saliva testing is that some individuals may have difficulty producing
273 adequate saliva for the test. Saliva is also a more challenging specimen for the laboratory staff to handle
274 and requires judgement about thickness to ensure the correct volume is pipetted, with a chance of an
275 under-pipetted sample, due to viscosity or bubbles, leading to a false-negative result, as well as
276 increased likelihood of extraction failure. Initially, mucolyse was added to individual thick saliva
277 specimens prior to extraction, but data obtained during our pooling validation showed that proteinase K
278 digestion for individual thick samples prior to extraction was just as effective. Therefore, thick
279 specimens and pooled specimens follow the same processing procedure.

280
281 When evaluating the effectiveness of saliva collection, it is important to define which individuals are to
282 be captured by the testing. Is the goal to detect anyone who has an infection with the virus or to detect
283 those more likely to be infectious, reported to be Ct <35 in several studies (28-30), with other studies
284 reporting as low as <24 (31). When comparing across published studies, the agreement between reports

285 might increase if considering only samples with higher viral load. For these cases, the consensus
286 appears to be that saliva is an acceptable and convenient method of testing. We conclude that saliva
287 testing would detect employees who were most likely to be infectious to others and that saliva would be
288 an adequate screening approach, although we encourage employees to opt for mid-turbinate collection,
289 if they are willing, as it appears to be a more sensitive approach. Saliva testing is not used for individual
290 patient diagnosis at our institution.

291

292 **Acknowledgments:**

293 We thank the NIH car line team for assistance with sample collection, the clinical laboratory
294 technologists in the Departments of Laboratory Medicine and Transfusion Medicine for performing
295 assays, and the departmental support staff for managing paperwork related to the IRB protocol. We
296 thank Masashi Waga and the MedStar Washington Hospital Center laboratory staff for providing lab
297 data and samples after routine testing, and Tricia Coffey, Karen Kaczorowski, and Amanda Grove for
298 assistance with patient registration. We would like to thank Larry Tabak, Janice Lee, Blake Warner, and
299 Pavel Khil for helpful discussions.

300 KMF, DKH, SK, T Miller, TNP, study conception and design; KMF, BB, SD, AFL, TNP, AMZ, T Moriarty, SS,
301 PT, GW collection of samples; KMF, SD, AFL, AMZ, VD, supervision of assays; KMF, BB, SD, CS, collection
302 of data, performance of data analysis, and interpretation of data; KMF, BB, manuscript writing; AFL,
303 TNP, SD, SK, VD, AMZ, manuscript editing. All authors reviewed and approved the manuscript.

304 We declare that we have no conflicts of interest. This work was supported in part by the Intramural
305 Research Program of the National Institutes of Health Clinical Center. This project has been funded in
306 part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract
307 No. 75N910D00024, Task Order No., Task Order No. 75N91019F00130. The content of this publication

308 does not necessarily reflect the views or policies of the Department of Health and Human Services, nor
309 does mention of trade names, commercial products, or organizations imply endorsement by the
310 U.S. Government.

311

312 **References**

- 313 1. Johns Hopkins University and Medicine. Covid-19 Dashboard by the Center for Systems Science
314 and Engineering (CSSE) at Johns Hopkins University. <https://coronavirus.jhu.edu/map.html>.
315 Accessed September 20, 2020.
- 316 2. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir SM. 2020. Self-
317 Collected Anterior Nasal and Saliva Specimens versus Healthcare Worker-Collected
318 Nasopharyngeal Swabs for the Molecular Detection of SARS-CoV-2. J Clin Microbiol
319 doi:10.1128/JCM.01824-20.
- 320 3. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami S, Barati S,
321 Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M, Yip L, Zhong XZ, McGeer
322 AJ, Mubareka S, Toronto Invasive Bacterial Diseases Network C-I. 2020. Sensitivity of
323 nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome
324 coronavirus 2 (SARS-CoV-2). Clin Infect Dis doi:10.1093/cid/ciaa848.
- 325 4. Landry ML, Criscuolo J, Peaper DR. 2020. Challenges in use of saliva for detection of SARS CoV-2
326 RNA in symptomatic outpatients. J Clin Virol 130:104567 doi: 10.1016/j.jcv.2020.104567
- 327 5. Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling and
328 Testing Clinical Specimens for COVID-19. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html#specimen)
329 [nCoV/lab/guidelines-clinical-specimens.html#specimen](https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html#specimen). Accessed September 20, 2020.

- 330 6. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, Warren
331 JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P, Venkataraman A, Lu-
332 Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J,
333 White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE,
334 Park A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD,
335 Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A, Grubaugh ND, et al. 2020. Saliva
336 or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *N Engl J Med*
337 doi:10.1056/NEJMc2016359.
- 338 7. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, Fasano M, Sessa F, Tettamanti
339 L, Carinci F, Maurino V, Rossi A, Tagliabue A, Baj A. 2020. Saliva is a reliable tool to detect SARS-
340 CoV-2. *J Infect* 81:e45-e50 doi: 10.1016/j.jinf.2020.04.005.
- 341 8. Byrne RL, Kay GA, Kontogianni K, Aljayyousi G, Brown L, Collins AM, Cuevas LE, Ferreira DM,
342 Fraser AJ, Garrod G, Hill H, Hughes GL, Menzies S, Mitsi E, Owen SI, Patterson EI, Williams CT,
343 Hyder-Wright A, Adams ER, Cubas-Atienzar AI. 2020. Saliva Alternative to Upper Respiratory
344 Swabs for SARS-CoV-2 Diagnosis. *Emerg Infect Dis* 26(11) doi: 10.3201/eid2611.203283.
- 345 9. Iwasaki S, Fujisawa S, Nakakubo S, Kamada K, Yamashita Y, Fukumoto T, Sato K, Oguri S, Taki K,
346 Senjo H, Sugita J, Hayasaka K, Konno S, Nishida M, Teshima T. 2020. Comparison of SARS-CoV-2
347 detection in nasopharyngeal swab and saliva. *J Infect* 81:e145-e147 doi:
348 10.1016/j.jinf.2020.05.071.
- 349 10. McCormick-Baw C, Morgan K, Gaffney D, Cazares Y, Jaworski K, Byrd A, Molberg K, Cavuoti D.
350 2020. Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic

- 351 Patients Using Cepheid Xpert Xpress SARS-CoV-2. *J Clin Microbiol* 58(8):e01109-20. doi:
352 10.1128/JCM.01109-20.
- 353 11. Miguères M, Mengelle C, Dimeglio C, Didier A, Alvarez M, Delobel P, Mansuy JM, Izopet J. 2020.
354 Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic
355 carriers. *J Clin Virol* 130:104580 doi: 10.1016/j.jcv.2020.104580.
- 356 12. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, Horiuchi M, Kato K, Imoto
357 Y, Iwata M, Mimura S, Ito T, Tamura K, Kato Y. 2020. Clinical Evaluation of Self-Collected Saliva
358 by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-
359 Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19. *J Clin*
360 *Microbiol* 58(9):e01438-20. doi: 10.1128/JCM.01438-20.
- 361 13. Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G, Sukswan W,
362 Sungkanuparph S, Phuphuakrat A. 2020. Saliva sample as a non-invasive specimen for the
363 diagnosis of coronavirus disease 2019: a cross-sectional study. *Clin Microbiol Infect*
364 doi:10.1016/j.cmi.2020.05.001
- 365 14. Procop GW, Shrestha NK, Vogel S, Van Sickle K, Harrington S, Rhoads DD, Rubin BP, Terpeluk P.
366 2020. A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of
367 SARS-CoV-2 in Symptomatic Patients. *J Clin Microbiol* doi:10.1128/JCM.01946-20.
- 368 15. Rao M, Rashid FA, Sabri F, Jamil NN, Zain R, Hashim R, Amran F, Kok HT, Samad MAA, Ahmad N.
369 2020. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-
370 CoV-2. *Clin Infect Dis* doi:10.1093/cid/ciaa1156.

- 371 16. Skolimowska K, Rayment M, Jones R, Madona P, Moore LSP, Randell P. 2020. Non-invasive saliva
372 specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low
373 prevalence. *Clin Microbiol Infect* doi:10.1016/j.cmi.2020.07.015.
- 374 17. Williams E, Bond K, Zhang B, Putland M, Williamson DA. 2020. Saliva as a Noninvasive Specimen
375 for Detection of SARS-CoV-2. *J Clin Microbiol* 58(8):e00776-20 doi: 10.1128/JCM.00776-20.
- 376 18. Zhu J, Guo J, Xu Y, Chen X. 2020. Viral dynamics of SARS-CoV-2 in saliva from infected patients. *J*
377 *Infect* 81:e48-e50 doi: 10.1016/j.jinf.2020.06.059.
- 378 19. Uwamino Y, Nagata M, Aoki W, Fujimori Y, Nakagawa T, Yokota H, Sakai-Tagawa Y, Iwatsuki-
379 Horimoto K, Shiraki T, Uchida S, Uno S, Kabata H, Ikemura S, Kamata H, Ishii M, Fukunaga K,
380 Kawaoka Y, Hasegawa N, Murata M. 2020. Accuracy and stability of saliva as a sample for
381 reverse transcription PCR detection of SARS-CoV-2. *J Clin Pathol* doi:10.1136/jclinpath-2020-
382 206972.
- 383 20. Centers for Disease Control and Prevention. Research Use Only 2019–Novel Coronavirus (2019-
384 nCoV) Real-time RT-PCR Primers and Probes. [https://www.cdc.gov/coronavirus/2019-
385 ncov/lab/rt-pcr-panel-primer-probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html). Accessed September 21, 2020.
- 386 21. Vogels CBF, Brackney D, Wang J, Kalinich CC, Ott I, Kudo E, Lu P, Venkataraman A, Tokuyama M,
387 Moore AJ, Muenker MC, Casanovas-Massana A, Fournier J, Bermejo S, Campbell M, Datta R,
388 Nelson A, Dela Cruz C, Farhadian S, Ko A, Iwasaki A, Hui P, Liu C, Wyllie AL, Grubaugh N. 2020.
389 SalivaDirect: Simple and sensitive molecular diagnostic test for SARS-CoV-2 surveillance.
390 doi:10.1101/2020.08.03.20167791 %J medRxiv:2020.08.03.20167791.

- 391 22. Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF, Casanovas-Massana
392 A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M, Nelson A, Fournier J, Bermejo S,
393 Campbell M, Datta R, Dela Cruz CS, Farhadian SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB,
394 Wyllie AL. 2020. Simply saliva: stability of SARS-CoV-2 detection negates the need for expensive
395 collection devices. medRxiv doi:10.1101/2020.08.03.20165233.
- 396 23. Harikrishnan P. 2020. Saliva as a Potential Diagnostic Specimen for COVID-19 Testing. *J Craniofac*
397 *Surg* 31:e653-e655 doi: 10.1097/SCS.00000000000006724.
- 398 24. Becker D, Sandoval E, Amin A, De Hoff P, Diets A, Leonetti N, Lim YW, Elliott C, Laurent L,
399 Grzynski J, Lu J. 2020. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection
400 in the community setting. doi:10.1101/2020.05.11.20092338 %J
401 medRxiv:2020.05.11.20092338.
- 402 25. Das S, Lau AF, Youn JH, Khil PP, Zelazny AM, Frank KM. 2020. Pooled Testing for Surveillance of
403 SARS-CoV-2 in Asymptomatic Individuals. *J Clin Virol* 132:104619 doi:
404 10.1016/j.jcv.2020.104619.
- 405 26. Pasomsub E, Watcharananan SP, Watthanachockchai T, Rakmanee K, Tassaneetrithep B,
406 Kiertiburanakul S, Phuphuakrat A. 2020. Saliva sample pooling for the detection of SARS-CoV-2. *J*
407 *Med Virol* doi:10.1002/jmv.26460.
- 408 27. Watkins AE, Fenichel EP, Weinberger DM, Vogels CBF, Brackney DE, Casanovas-Massana A,
409 Campbell M, Fournier J, Bermejo S, Datta R, Dela Cruz CS, Farhadian SF, Iwasaki A, Ko AI,
410 Grubaugh ND, Wyllie AL. 2020. Pooling saliva to increase SARS-CoV-2 testing capacity.
411 doi:10.1101/2020.09.02.20183830 %J medRxiv:2020.09.02.20183830.

- 412 28. Huang CG, Lee KM, Hsiao MJ, Yang SL, Huang PN, Gong YN, Hsieh TH, Huang PW, Lin YJ, Liu YC,
413 Tsao KC, Shih SR. 2020. Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical
414 Specimens Tested for COVID-19. *J Clin Microbiol* 58(8):e01068-20 doi: 10.1128/JCM.01068-20.
- 415 29. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult D. 2020.
416 Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2
417 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* 39:1059-1061 doi:
418 10.1007/s10096-020-03913-9.
- 419 30. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M,
420 Gopal R. 2020. Duration of infectiousness and correlation with RT-PCR cycle threshold values in
421 cases of COVID-19, England, January to May 2020. *Euro Surveill* 25(32):2001483. doi:
422 10.2807/1560-7917.ES.2020.25.32.2001483.
- 423 31. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A,
424 Schiffman Z, Doan K, Bastien N, Li Y, Van Caesele PG, Poliquin G. 2020. Predicting infectious
425 SARS-CoV-2 from diagnostic samples. *Clin Infect Dis* doi:10.1093/cid/ciaa638.

426

427 **Figure 1 (A-C). Comparison of Cycle Threshold (Ct) values of N1 for NP versus SAL specimens.**

- 428 A. N1 Ct values for paired NP/MT and SAL samples (29 pairs). Pairs are connected by a line. The N1
429 Ct was set to 40 for samples for which N1 was not detected, indicating negative for SARS-CoV-2
430 RNA. Horizontal dashed line is at Ct=40, the assay cut off. P-value < 0.001 calculated by Wilcoxon
431 matched-pair signed rank test.

432 B. A lower median viral load was seen for SAL specimens compared with the median Ct for NP/MT
433 samples. Median and interquartile range are 26, (21-34) for NP/MT and 31, (29-37) for SAL
434 respectively. P-value <0.001.

435 C. RP Ct values for NP/MT and SAL specimens (424 pairs). Median and interquartile range are 24,
436 (23-25) for NP/MT and 22 (21-23) for saliva respectively. Horizontal dashed line is at Ct=40, the
437 assay cut off. P value < 0.001 calculated by Wilcoxon matched-pairs signed rank test.

438

439 **Figure 2 (A-C). Comparison of Cycle Threshold (Ct) values for individual and pooled saliva specimens**
440 **on different testing platforms.**

441 A. Ct values for paired individual and pooled samples (easyMAG/ABI 7500) for 41 pairs.

442 B. Ct values for paired individual (easyMAG/ABI 7500) and pooled samples (Hologic Panther) for 30
443 pairs.


444 C. Ct values for paired individual (easyMAG/ABI 7500) and pooled samples (Roche COBAS 6800) for
445 39 pairs. For A-C, pairs are connected by a line. Horizontal dashed line is at Ct=40, the assay cut
446 off. P-value < 0.001 calculated by Wilcoxon matched- pair signed rank test. For C,D, the pooled
447 Ct was set to 40 for samples in which N1 was not detected including those negative for SARS-
448 CoV-2 RNA.

449

Table 1. SARS-CoV-2 Real-time RT PCR results for paired NP/MT and saliva

	NP Positive/Indeterminate	NP Negative	Total
Saliva Positive/ Indeterminate	30	1	31
Saliva Negative	7	421	428
Total	37	422	459

Figure 1 (A-C)



C. RP Ct Values for Sample Pairs






Figure 2 (A-C)

A. CDC Assay-EasyMag/ABI 7500



B. Hologic Panther



C. Roche COBAS 6800

